New drug trial aims to protect kidneys from damage
NCT ID NCT07323095
Summary
This study is testing whether an experimental drug called ABP-671 can help protect kidney function in people who have both chronic kidney disease and high uric acid levels. About 75 participants will receive either the drug or a placebo for 28 weeks while researchers measure changes in kidney health markers. The main goal is to see if the drug safely reduces protein in urine, which indicates better kidney protection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, 100000, China
-
Genesis Research services
Newcastle, New South Wales, 2019, Australia
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100000, China
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200000, China
-
Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
-
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, 100000, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.